Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC)

被引:24
作者
Andres, R. [1 ]
Pajares, I. [1 ]
Balmana, J. [2 ]
Llort, G. [3 ]
Ramon y Cajal, T. [4 ]
Chirivella, I. [5 ]
Aguirre, E. [6 ]
Robles, L. [7 ]
Lastra, E. [8 ]
Perez-Segura, P. [9 ]
Bosch, N. [2 ]
Yaguee, C. [3 ]
Lerma, E. [4 ]
Godino, J. [10 ]
Miramar, M. D. [11 ]
Moros, M. [1 ]
Astier, P. [12 ]
Saez, B. [10 ]
Vidal, M. J. [13 ]
Arcusa, A. [3 ]
Ramon y Cajal, S. [1 ]
Calvo, M. T. [11 ]
Tres, A. [1 ]
机构
[1] Hosp Clin Lozano Blesa, Serv Oncol Med, Zaragoza 50009, Spain
[2] Hosp Vall dHebron Barcelona, Barcelona, Spain
[3] Inst Oncol Valles, Catalonia, Spain
[4] Hosp Santa Creu & San Pau Barcelona, Barcelona, Spain
[5] Hosp Clin Valencia, Valencia, Spain
[6] Hosp Arnau de Vilanova Lerida, Lleida, Spain
[7] Hosp Univ 12 Octubre, Madrid, Spain
[8] Hosp G Yague Burgos, Burgos, Spain
[9] Hosp Clin San Carlos Madrid, Madrid, Spain
[10] Aragon Hlth Sci Inst, Zaragoza, Spain
[11] Hosp Univ Miguel Servet, Zaragoza, Spain
[12] Ctr Salud San Pablo, Zaragoza, Spain
[13] Hosp Valle De Hebron, Barcelona, Spain
关键词
Triple negative breast cancer; BRCA1; Hereditary breast cancer; ESTROGEN-RECEPTOR; HISTOPATHOLOGICAL FEATURES; TUMORS; AGE; INDIVIDUALS; PREDICTION; PATHOLOGY;
D O I
10.1007/s12094-013-1070-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BRCA1-associated breast cancers have been associated to a triple-negative phenotype. The prevalence of BRCA1 germline mutations in young onset TNBC based on informativeness of family history has not been reported. From January 2008 to May 2009 were collected blood and tumor samples from patients with TNBC younger than 50 years and without a family history of breast and ovarian cancer in first- and second-degree relatives. Analysis of BRCA1 germline mutations was made. Age at diagnosis and informativeness of family history (presence of female in first- and second-degree relatives alive until age 45) was collected in all cases. Immunohistochemistry of basal-like features was performed centrally in all available tumors. Seven pathogenic mutations were detected in 92 patients (7.6 %), two of them in patients younger than 35 years (28.6 %) (Fisher's exact test, p = 0.631). Three non-classified variants were detected (3.2 %). Family history was informative in two patients with a pathogenic mutation (28.6 %) and not informative in five (71.4 %) (Fisher's exact test, p = 0.121). Of the seven patients with a pathogenic mutation, four had a basal-like phenotype. Patients with apparently sporadic TNBC younger than 50 years and a non-informative family history are candidates for germline genetic testing of BRCA1.
引用
收藏
页码:280 / 284
页数:5
相关论文
共 23 条
[1]  
Chang J, 2001, CLIN CANCER RES, V7, P1739
[2]   Basal Cytokeratin and Epidermal Growth Factor Receptor Expression Are Not Predictive of BRCA1 Mutation Status in Women With Triple-negative Breast Cancers [J].
Collins, Laura C. ;
Martyniak, Anthony ;
Kandel, Michaela J. ;
Stadler, Zsofia K. ;
Masciari, Serena ;
Miron, Alexander ;
Richardson, Andrea L. ;
Schnitt, Stuart J. ;
Garber, Judy E. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2009, 33 (07) :1093-1097
[3]   Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families [J].
Eerola, H ;
Heikkilä, P ;
Tamminen, A ;
Aittomäki, K ;
Blomqvist, C ;
Nevanlinna, H .
BREAST CANCER RESEARCH, 2005, 7 (04) :R465-R469
[4]   Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families [J].
Eerola, H ;
Heikkilä, P ;
Tamminen, A ;
Aittomäki, K ;
Blomqvist, C ;
Nevanlinna, H .
BREAST CANCER RESEARCH, 2005, 7 (01) :R93-R100
[5]  
Eisinger F, 1999, INT J CANCER, V84, P263, DOI 10.1002/(SICI)1097-0215(19990621)84:3<263::AID-IJC11>3.0.CO
[6]  
2-G
[7]   Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing [J].
Farshid, Gelareh ;
Balleine, Rosemary L. ;
Cummings, Margaret ;
Waring, Paul .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (11) :1357-1366
[8]   Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families [J].
Ford, D ;
Easton, DF ;
Stratton, M ;
Narod, S ;
Goldgar, D ;
Devilee, P ;
Bishop, DT ;
Weber, B ;
Lenoir, G ;
Chang-Claude, J ;
Sobol, H ;
Teare, MD ;
Struewing, J ;
Arason, A ;
Scherneck, S ;
Peto, J ;
Rebbeck, TR ;
Tonin, P ;
Neuhausen, S ;
Barkardottir, R ;
Eyfjord, J ;
Lynch, H ;
Ponder, BAJ ;
Gayther, SA ;
Birch, JM ;
Lindblom, A ;
Stoppa-Lyonnet, D ;
Bignon, Y ;
Borg, A ;
Hamann, U ;
Haites, N ;
Scott, RJ ;
Maugard, CM ;
Vasen, H .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (03) :676-689
[9]   Estrogen receptor status in BRCA1- and BRCA2-related breast cancer:: The influence of age, grade, and histological type [J].
Foulkes, WD ;
Metcalfe, K ;
Sun, P ;
Hanna, WM ;
Lynch, HT ;
Ghadirian, P ;
Tung, N ;
Olopade, OI ;
Weber, BL ;
McLennan, J ;
Olivotto, IA ;
Bégin, LR ;
Narod, SA .
CLINICAL CANCER RESEARCH, 2004, 10 (06) :2029-2034
[10]   Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer [J].
Foulkes, WD ;
Stefansson, IM ;
Chappuis, PO ;
Bégin, LR ;
Goffin, JR ;
Wong, N ;
Trudel, M ;
Akslen, LA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (19) :1482-1485